EUCTR2012-001221-27-AT进行中（未招募）1 期
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins - Odyssey - Alternative
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with primary hypercholesterolemia (heFH* or non-FH) with moderate, high or very high CV risk** and a history of statin intolerance***
- •* Diagnosis of heFH must be made either by genotyping or by clinical criteria. For patients who are not genotyped, the clinical diagnosis must be a certain/definite diagnosis and may be based on either the Simon Broome criteria or the WHO/Dutch Lipid Network criteria.
- •** Moderate, high, and very high CV risk as defined in section 4.2.
- •*** Definition of statin intolerance: Inability to tolerate at least 2 previous statins at the lowest approved daily dose due to skeletal muscle-related symptoms, other than those due to strain or trauma, such as pain, aches, weakness, or cramping, that began or increased during statin therapy and stopped when statin therapy was discontinued.
- •2. Provide signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Calculated serum LDL-C <70 mg/dL (1.81 mmol/L) and very high CV risk at the screening visit
- •2. Calculated serum LDL-C <100 mg/dL (2.59 mmol/L) and high or moderate CV risk at the screening visit
- •3. A 10-year fatal CVD risk SCORE < 1% at the screening visit
- •4. Use of a statin that is at or above the lowest approved daily dose within 4 weeks prior to the screening visit
- •5. Experienced skeletal muscle-related adverse event(s), other than those due to strain or trauma during the 4-week single-blind placebo run-in
- •6. Experiencing a skeletal muscle-related adverse event(s), other than those due to strain or trauma at the time of screening, start of single-blind placebo run-in period, or day 1/week 0
- •7. Not on a stable dose of LMT for at least 4 weeks and/or fenofibrate for at least 6 weeks, as applicable, prior to the screening visit or from screening to randomization, as applicable
- •8. Use of fibrates, other than fenofibrate, within 6 weeks of the screening visit
- •9. Use of nutraceuticals or over-the-counter (OTC) therapies known to affect lipids, at a dose/amount that has not been stable for at least 4 weeks prior to the screening visit or between the screening and randomization visits
- •10. Use of red yeast rice from the screening visit to the end-of-study visit
- •11. Use of analgesics for which the dose is not planned to be stable from the screening visit to the end-of-study visit
- •12. Diagnosis of fibromyalgia
- •13. History of severe neuropathic pain
- •14. History of rheumatological disease associated with symptoms that may be confounded with symptoms of statin intolerance, e.g., rheumatoid arthritis
- •15. History of myalgia or myopathy that began or increased during treatment with lipid modifying therapy (LMT), other than statin therapy, and stopped when the LMT was discontinued
- •16. Known history of seizure disorder
- •17. History of previous transplant surgery
- •18. Use of medications that require intramuscular administration, or planned intramuscular injections during the study
- •19. Known history of myopathy, other than statin-associated myopathy
- •20. History of rhabdomyolysis (defined as evidence of organ damage with creatine kinase (CK) > 10,000 IU/L)
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of REGN727/SAR236553 in patients with primary hypercholesterolemia who are intolerant to statinsEUCTR2012-001221-27-ITREGENERON PHARMACEUTICALS, INC.250
撤回
3 期
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statinshigh cholesterolprimary hypercholesterolemia100274241001331710003216NL-OMON39721Regeneron Pharmaceuticals Inc.66
进行中（未招募）
1 期
Efficacy and Safety of REGN727/SAR236553 in patients with primary hypercholesterolemia who are intolerant to statinsPatients with primary hypercholesterolemia and moderate, high or very high cardiovascular (CV) risk who are intolerant to statinsMedDRA version: 19.0 Level: PT Classification code 10020603 Term: Hypercholesterolaemia System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-001221-27-GBRegeneron Pharmaceuticals, Inc.314
进行中（未招募）
不适用
Efficacy and Safety of REGN727/SAR236553 in patients with primary hypercholesterolemia who are intolerant to statinsEUCTR2012-001221-27-NORegeneron Pharmaceuticals, Inc.250
进行中（未招募）
不适用
A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Arthritis Non-Inferiority Study of LT-NS001 versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates - Nature Trialosteoarthritis of the kneeEUCTR2009-018029-57-GBogical Therapeutics Inc.534